Varian Medical Systems, Inc. (VAR) October 04, 2011 7:30 am ET Executives Lester D. Boeh - Vice President of Emerging Businesses and Vice President of Oncology Systems Security & Inspection Business Unknown Executive - Dow R. Wilson - Chief Operating Officer Spencer R. Sias - Vice President of Corporate Communications & Investor Relations Kolleen T. Kennedy - Senior Vice President and President of Oncology Systems Timothy E. Guertin - Chief Executive Officer, President and Executive Director Analysts Amit Bhalla - Citigroup Inc, Research Division Vivian Cervantes - Kaufman Bros., L.P., Research Division Anthony Petrone - Jefferies & Company, Inc., Research Division Jeffrey D. Johnson - Robert W. Baird & Co. Incorporated, Research Division Unknown Analyst - PresentationTimothy E. Guertin
Good morning, everybody. I guess the mics are working. Sorry about my voice. I've had about 10,000 hours of conversations with people in the last 2 days, so it's slowly going away. So let me do some introductions. As you've probably read from the press release, we've made some organizational changes. We promoted Dow Wilson to be -- and that is Dow right there, to be Chief Operating Officer for the company. So the business units will be reporting to Dow and -- the corporate operations and Dow will, of course, continue to report to me. Kolleen Kennedy, who is the Head of our Customer Support Operations, it's about a $600 million business. Kolleen is sitting right here, will be Head of the Oncology Business Unit. Lester Boeh, who is right here, is present, and he is the Head of our Merchant Businesses. And these folks will all be talking to you today. In addition, we have Pat Joda with us. Pat, say hi. Pat will be replacing Kolleen in the Services business. We didn't talk a lot about Pat, but Pat came to us from GE a few years ago and he ran our operations for our Oncology Systems for a number of years and lately has been the Head of the Engineering Operations so he is well positioned and highly experienced executive. So we're glad we have a much deeper bench I think than we've ever had before as a company and this is very nice to see. So now I'm going to let all of this deep-bench talk to you directly. And so with that, we'll begin with Dow.